Artelo Biosciences (ARTL) said Wednesday its candidate drug ART27.13 showed "promising pre-clinical results" in protecting human muscle cells from...
Artelo Biosciences (ARTL) said Monday it agreed to expand its partnership with Trinity College Dublin with a focus on investigating the cellular biology of...
Artelo Biosciences (ARTL) said Wednesday the US Patent and Trademark Office issued a notice of allowance for a patent application pertaining to ART12.11, a...
Artelo Biosciences (ARTL) reported that the UK government no longer considers the company's lead clinical cannabinoid ART27.13 a Schedule 1 controlled...
| Address | 505 Lomas Santa Fe Solana Beach, California 92075 |
| Phone | +1.858.925.7049 |
| Number of Employees | 2 |
| Recent SEC Filing | 06/02/2022 424B3 |
| President, CEO, CFO, Secretary & Treasurer | Gregory D. Gorgas |
| Vice President-Finance & Operations | Randy Schreckhise |
| Chief Medical Officer | Steven D. Reich |
| Chief Scientific Officer & Senior Vice President | Andy Yates |
| Price Open | $0.33 |
| Previous Close | $0.33 |
| 52 Week Range | $0.30 - 1.32 |
| Market Capitalization | $14.4 M |
| Shares Outstanding | 42.3 M |
| Sector | Health Technology |
| Industry | Pharmaceuticals: Major | Next Earnings Announcement | N/A |
| Call Open Interest (1d)* |  |
| Put Open Interest (1d)* | |
| Call Volume (1d)* | |
| Put Volume (1d)* | |
| Put Call Open Interest Ratio (1d)* | |
| Put Call Volume Ratio (1d)* | |
| * Data delayed by up to 15 minutes |
| Price / Earnings | N/A |
| Earnings per Share | -$0.33 |
| Beta vs. S&P 500 | N/A |
| Revenue | $0.00 |
| Net Profit Margin | N/A |
| Return on Equity | -50.91% |
| Buy | |
| Overweight | |
| Hold | |
| Underweight | |
| Sell | |
Consensus Recommendation | |
